The GLP-1 Ceiling and GIP Dividend: Unraveling the Cardio-Metabolic Paradox in SURPASS-CVOT - PubMed
5 hours ago
- #SURPASS-CVOT
- #tirzepatide
- #GLP-1 receptor agonist
- The article discusses the cardio-metabolic paradox in the SURPASS-CVOT trial.
- It focuses on GLP-1 receptor agonists and GIP/GLP-1 dual agonists, specifically tirzepatide.
- The authors report no conflicts of interest relevant to the paper's contents.